iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Handok to market Biocon's weight loss drug in South Korea

24 May 2024 , 12:59 PM

On Friday, Biocon Ltd. said that it has inked a supply and exclusive licencing deal with Handok of South Korea for the commercialization of its sophisticated medication, synthetic ligliglutide, which is used to treat chronic weight control.

According to the agreement, Handok, a specialty pharmaceutical company, will be in charge of getting regulatory approval and commercialization in the South Korean market, while Biocon will handle the development, production, and supply of the drug product, the company stated in a statement.

Biocon CEO and Managing Director Siddharth Mittal stated, “… the partnership with Handok, which will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, synthetic Liraglutide.”

He went on to say, “This also aligns with our commitment to expand our portfolio of innovative, affordable medicines to address the unmet needs of patients around the world.”

One of the top companies in South Korea for diabetes management is Handok, which provides a range of services from diagnosis to care and treatment.

“Liraglutide is a significant medication used to treat obesity and diabetes. Handok Chairman YoungJin Kim stated, “Our partnership with Biocon will allow Handok to broaden its line of business into the obesity industry, which will assist patients and strengthen our competitive edge.

According to Biocon, the IQVIA MAT Q4 2023 indicates that the total addressable market opportunity for Liraglutide in South Korea is almost USD 47 million.

For feedback and suggestions, write to us at editorial@iifl.com

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

Related Tags

  • Biocon
  • Handok
  • South Korea
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.